Malin Corporation plc (ISE:MLC) acquired 35% stake in Wren Therapeutics Ltd for £3 million on August 3, 2016. Consideration is payable in cash. Under the terms of the transaction, Malin has an option to increase its shareholding in Wren to 67%. Malin CEO, Kelly Martin and Malin Chief Investment Officer, Adrian Howd, Ph.D, will also join the Board of Wren. Sam Cohen, Ph.D., Malin Chief Technology Officer and Research Fellow of St John's College, Cambridge. Malin Corporation plc (ISE:MLC) completed the acquisition of 33% stake in Wren Therapeutics Ltd on August 3, 2016.